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Abstract
The antiphospholipid syndrome is characterized by the presence in serum of autoantibodies against h2GPI. Although the role of h2GPI in
the pathogenesis of antiphospholipid antibody syndrome (APS) is well recognized, its exact physiological functions still remain undisclosed.
Several interactions of h2GPI with components of the coagulation cascade have been proposed, resulting in both procoagulant and
anticoagulant effects. Additionally, h2GPI has been implicated in the mechanism of recurrent fetal loss entailed in APS. Recently, using a
homologous recombination approach, reproduction of mice homozygous for deletion of the b2GPI gene has been feasible. h2GPI knockout
mice offer a valuable tool for revealing the physiological role of the protein. These mice show decreased in vitro ability for thrombin
generation. Furthermore, although mice lacking h2GPI are fertile, the success of early pregnancy is moderately compromised and functional
h2GPI is believed necessary for optimal implantation and placental morphogenesis.
D 2004 Published by Elsevier Inc.
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Introduction
The antiphospholipid antibody syndrome (APS) is deter-
mined by a constellation of clinical features (mainly recur-
rent venous and arterial thrombosis, recurrent fetal loss, and
livedo reticularis) in combination with the detection of
antiphospholipid antibodies (aPL) in the sera of affected
patients [1,2]. The disorder may occur alone (referred as the
primary APS) or in association with systemic lupus eryth-
ematosus (SLE), other autoimmune diseases, and rarely with
other diseases, certain infections, and drugs (secondary
APS) [2–5]. The aPL can be detected either via the lupus
anticoagulant (LA) in vitro bioassay or via commercially
available ELISA assays for antibodies interacting with
cardiolipin and/or h2 glycoprotein-I (h2GPI).
The plasma protein h2GPI is a phospholipid binding
protein with anticoagulant properties. h2GPI constitutes the
major antigenic target for aPL circulating in the serum of
APS patients [6]; therefore, the term ‘‘antiphospholipid
antibodies’’ is actually a misnomer. It is currently evident
that the h2GPI ELISA has greater specificity and positive
predictive value than the cardiolipin ELISA for the diagno-
sis of clinically significant APS [7,8]. These data confirmed
previous experimental results on the role of h2GPI-depen-
dent aPL in distinguishing between APS occurring in the
setting of autoimmune diseases and the transient occurrence
of aPL associated with infections [9]. In addition, it has been
shown that most cases of clinically significant LA are
associated with concomitant presence of anti-h2GPI anti-
bodies in the sera of APS patients [10,11]. Taken together,
these data argue for a key role of h2GPI in the molecular
pathophysiology of APS (summarized in Fig. 1).
b2 glycoprotein-I
Protein chemistry
h2GPI is a single chain glycoprotein, with a mass of
approximately 54 kDa [12]. Its 326 amino acid sequence
consists of five structurally similar short consensus repeat
(SCR) domains [13]. This characterizes h2GPI as a member
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of the complement control protein family [14]. The first four
domains are able to form disulfide bridges, forming a
‘‘looped-back’’ configuration (known also as a sushi do-
main) [15]. The domains I–II are of unknown function and
project away from the phospholipid surface into the plasma
space [16]. The central portion (domains III and IV) is
heavily glycosylated, separating the phospholipid binding
site (domain V) from domains I–II [16,17]. Both domains I
and IV have been suggested to contain the major epitopic
region for most anti-h2GPI autoantibodies [18,19].
The fifth domain of h2GPI contains a positively charged
(lysine-rich) region and also a hydrophobic loop terminal
area predicted to be surface exposed [16,17]. There is ample
evidence that both these regions on domain V mediate the
phospholipid binding properties of h2GPI: Site-directed
mutagenesis of Lys residues in the lysine-rich region (amino
acids 281–288) abolishes the binding of h2GPI to CL,
inhibiting also the binding of antibodies to h2GPI in a CL
ELISA [20]. Likewise, cleavage by both plasmin and (less
effectively) factor Xa has been demonstrated to occur at the
terminal region of domain V (Lys 317-Thr 318) [21,22].
This cleavage has been also predicted by modeling to affect
the position of the lysine-rich region, which is considered as
the main phospholipid binding region of h2GPI [20] (Fig.
1). Not surprisingly, therefore, the cleaved h2GPI shows
reduced ability to bind phospholipids in vivo [21,22].
Additionally, genetic polymorphisms resulting in alterations
of the 20 residue tail disrupt the integrity of configuration of
domain V, thus limiting the ability of h2GPI to bind
negatively charged molecules such as phosphatidylserine
[23]. Recently, it was shown that heparin binds to the lysine-
rich site located within the fifth domain of h2GPI [24].
Moreover, heparin at therapeutic concentrations is able to
enhance the plasmin-mediated cleavage of the C-terminal
region (Lys 317-Thr 318) of h2GPI [24]. These data indicate
the importance of the fifth domain of h2GPI for binding to
anionic phospholipids and heparin.
h2GPI is one of the most abundant proteins in human
serum, with a mean serum level of 200 mg/l, second only to
fibrinogen among the plasma proteins involved in clotting
[25]. There is a wide range of interindividual variation in
h2GPI plasma levels, arising from nucleotide polymorphisms
of the b2GPI gene [26,27] that maps to chromosome arm 17q
[13]. The protein exists in the circulation predominantly in
the free form, but also in lipid-bound form, and satisfies the
criteria for classification as an apolipoprotein [28]; hence, it
has also been termed apolipoprotein H [29]. h2GPI is
synthesized mainly in the liver [13] and also in intestinal
epithelial cells [30] and placenta cells [31]. h2GPI in plasma
is able to bind to anionic or zwitterionic phospholipid without
calcium ions. The precise function of the protein in plasma is
still unresolved, although h2GPI in vitro binds to anionic
phospholipids, producing an apparent anticoagulant effect by
occupying the procoagulant binding sites [32]. Interestingly,
individuals without detectable h2GPI have been identified
who appear clinically well [33,34].
b2GPI and coagulation factors
A number of possible in vitro functions of h2GPI for the
control of intravascular clot formation have been proposed.
These include both procoagulant [35,36] and anticoagulant
activity [37,38] at different stages of the coagulation cascade.
Similarly, data on the role of antibodies against h2GPI are
incongruous [39,40]. Interestingly, h2GPI-deficient individ-
uals are apparently not at risk of thrombosis [34] and most of
their hemostatic and fibrinolytic markers are normal [41].
It seems therefore that the role of h2GPI in APS-related
thrombosis is rather more qualitative than quantitative, with
aPL possibly interfering with the physiological functions of
h2GPI, including the protein’s interactions with coagulation
factors. h2GPI normally inhibits the generation of factor Xa
in the presence of activated platelets, and the presence of
anticardiolipin antibodies results in protracted, unopposed
factor Xa generation [38]. On the other hand, plasmin and
factor Xa can cleave the positively charged sequence Lys
317-Thr 318 at the fifth domain of h2GPI, impairing the
ability of h2GPI to bind phospholipids [21,22]. Moreover,
heparin binding to the fifth domain of h2GPI, at concen-
trations achieved in vivo, greatly enhances the plasmin-
mediated cleavage of h2GPI [24].
Association of antibodies against h2GPI with protein C
activity has been reported by different groups [40,42,43];
however, a direct interaction between h2GPI and either
protein C or APC targets has not been demonstrated so far.
It has also been suggested that h2GPI inhibits factor XII
activation and that the inhibition is enhanced by anti-h2GPI
[44]. Furthermore, suppression of intrinsic fibrinolytic activ-
ity of the euglobulin fraction from normal plasma by h2GPI,
independent of factor XII, has been recently described and
the effect is reversed by monoclonal anti-h2GPI antibodies in
the presence of h2GPI [45]. Thus, h2GPI appears to not only
interact with factors of the coagulation cascade, but also
participate in the regulation of intrinsic fibrinolysis.
The relationship between h2GPI and factor XII is chal-
lenged by the frequent existence of antibodies to FXII in
patients with APS [46]. Similarly, antibodies have also been
detected against prothrombin, protein C, protein S, and
annexin V in patients with SLE-associated APS, moreover
as independent, significant risk factors for arterial thrombo-
sis, venous thrombosis, and fetal loss [47]. On the other
hand, associations of h2GPI with coagulation factors do not
necessarily entail any direct involvement of aPL in the
activation of the coagulation cascade for APS-related throm-
bosis. As long as the exact function of h2GPI remains
obscure, the extent of involvement of this molecule in the
coagulation cascade, together with the possible implications
of the existence of anti-h2GPI antibodies, is difficult to
accurately assess (Fig. 1).
b2GPI and pregnancy loss
Recurrent miscarriage constitutes one of the main fea-
tures of APS [1,2]; however, the pathogenic mechanisms
remain unknown and indeed evidence of a causal link has
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proven difficult to generate. Early experiments incubating
aPL with human placental trophoblast cells showed inhibi-
tion of proliferation and secretory activity was elicited by
antibodies reacting with h2GPI, confirming the involvement
of h2GPI in APS-related pregnancy loss, and suggesting that
h2GPI contains the critical antigenic determinants for anti-
cardiolipin antibodies [48]. Alternative hypotheses have
also been formulated: (1) aPL may prevent in vitro implan-
tation, after binding to trophectoderm of preimplantation
embryos [49]; (2) aPL may interfere with the ability of
h2GPI to mediate the activity of lipoprotein lipase [50], for
placental prostaglandin synthesis from maternal membrane
phospholipids [51]; and (3) h2GPI could react with oxi-
dized-LDL, facilitating the binding of aPL [52]; this induces
the uptake of oxidized-LDL by macrophages triggering
atherogenesis [53], and acute atherosis is a common finding
in the placental bed of complicated pregnancies [54].
Perhaps one of the most attractive potential mechanisms
to emerge is the recently described activation of endothe-
lial cells mediated through the annexin II receptor. Binding
of aPL to h2GPI on the endothelial cell surface activates
genes that result in adhesion molecule, proinflammatory
cytokine, and tissue factor up-regulation, ultimately induc-
ing a proinflammatory and a procoagulant phenotype in
endothelial cells [55] (Fig. 1). Interestingly, activation
mimics the cascade of events elicited by lipopolysaccha-
ride (LPS) or interleukin-1, and transient transfection
studies in immortalized endothelial cell lines now implicate
a toll-like receptor or interleukin-1 receptor in mediating
the NF kappa B-mediated signaling cascade triggered by
h2GPI ligation [56].
Experimental data from mouse models on the involve-
ment of aPL in APS-related pregnancy loss are conflicting.
Although initially it was postulated that passive transfer of
IgG fractions of human anticardiolipin antibodies to preg-
nant mice results in fetal death [57], such adverse effects
of human aPL on murine pregnancy were less successfully
reproduced in subsequent, similar studies [58,59]. It could
be hypothesized that coadministration of h2GPI to mice (as
a contaminant of the IgG preparations) might contribute to
this inconsistency. However, conflicting results have also
been obtained when mice were immunized with human
h2GPI. Immunization with h2GPI did induce aPL in mice;
however, it did not result in fetal loss and was not
associated with thrombocytopenia [60]. On the contrary,
adverse reproductive outcome was associated with h2GPI
immunization experiments in a later study, using the same
methodology [61]. Recently, complement-mediated placen-
tal injury was implicated in passive immunization studies
that demonstrated a requirement for complement C3 in
fetal loss and growth retardation elicited after injection of
human IgG class aPL to pregnant mice [62].
Absence of thrombocytopenia despite fetal loss [52]
could support the argument that platelet consumption in
placental thrombotic events is not the predominant mecha-
nism of recurrent miscarriages in APS. Even when labora-
tory data on human APS are reviewed, it is evident that the
sole existence of aPL is not sufficient for explaining
recurrent fetal loss in human APS: aPL are present in only
about one tenth of recurrent aborters [63], while the IgM
aCL assay may produce positive but clinically nonsignifi-
cant results in high proportions of normal pregnancies
[64,65].
The experimental data in mice thus do not clarify whether
aPL are associated with pregnancy loss. Key questions
remain concerning the specificity of passively transferred
human aPL in mice. Some antibody preparations may react
only with human h2GPI, while others are also able to
recognize epitopes on murine h2GPI or even other mole-
cules. Thus, neither human clinical studies nor animal
Fig. 1. Mechanism of action of anti-h2GPI autoantibodies from APS patients.
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models have provided definite evidence for a role of h2GPI
in pregnancy outcome, and importantly, the extent to which
antibodies act through neutralizing function of h2GPI versus
triggering a h2GPI-mediated activation event has not been
established.
b2GPI—lessons from knockout mice
Mouse models for the role of b2GPI in APS
The mouse offers a good model for studying APS. Mice
spontaneously develop clinical features of SLE [66] and
also manifestations of APS [67,68]. These mice, in addition
to SLE type autoantibodies (ANA, anti-ssDNA, and anti-
dsDNA) [69,70], develop aCL antibodies that are h2GPI
dependent [67] and direct anti-B2GPI antibodies [68].
Although initial attempts for inducing SLE in mice were
incongruous [71–73], several murine models of APS have
now been described. Several groups have replicated aspects
of pregnancy pathology in mouse models, albeit with the
caveats described above. Moreover, transferred aPL have
been reported to confer thrombotic status in mice [74];
however, this effect is technically difficult to estimate
accurately, as an important limitation arises from the fact
that mice are difficult to venesect repetitively. Treatment of
mice, suffering from experimentally induced APS, with
IVIG inhibits the thrombogenic effects of aPL in vivo and
reduces the levels of aCL in the circulation. Blockade
of stimulatory Fc gammaR on inflammatory cells is not
necessary for this effect [75].
It must be emphasized that considerable homology in
structure exists between human and mouse h2GPI [1,76].
This assigns the mouse as a very useful tool for elucidating
the role of h2GPI, both in homeostasis and in APS. The
assumption that a physiological role exists is reinforced by
the high degree of conservation of h2GPI among mammals
[1] together with the abundance of h2GPI in plasma [25].
Ontogenetically, either of these two would be unlikely if an
important role for h2GPI was not allocated. However, as
already mentioned, the precise role of h2GPI is not fully
elucidated: Apart from the ‘‘classical’’ hypothesis on h2GPI
binding to phospholipids (Fig. 1) interactions of h2GPI have
been described with coagulation molecules [22,24], annexin
II, and other endothelial proteins [77] and also with mole-
cules important for atheroma formation [78]. It is therefore
essential that research on h2GPI in mice should accommo-
date the diverse interactions of the protein.
Mice immunized with human h2GPI were reported to
develop high affinity polyclonal antibodies in both aCL
ELISA and then anti-h2GPI ELISA [79], probably as a
result of nonspecific charge-dependent binding [29]. Immu-
nization of mice with human h2GPI results in the generation
of antibodies reacting with human, bovine, and murine
h2GPI. The loss of tolerance to mouse h2GPI is attributable
to the high interspecies homology of h2GPI. Consequently,
it was speculated that a molecular mimicry mechanism
could be involved in APS [80], postulating that infection
may act to trigger initiation of autoimmune process [81,82].
This theory, however, does not entirely explain the common
transient occurrence of aPL after infections and the different
clinical behavior of this phenomenon, as compared to the
APS. Ultimately, further experimental elaboration is re-
quired to solidly support such a role for h2GPI in the
pathogenesis of APS.
Generation of b2GPI null mutant mice
New perspectives into research on h2GPI have emerged
after the recent generation and initial characterization of
transgenic mice unable to express h2GPI [83], obtained
using a homologous recombination approach [76]. Mice
with a deletion of the b2GPI gene proceed normally to
adulthood and show no clear tendency to thrombosis;
however, they exhibit impaired thrombin generation upon
activation of the extrinsic clotting cascade in defibrinated
plasma [83]. The findings from experiments with h2GPI-
deficient mice on the role of h2GPI will be discussed next.
Pregnancy in b2GPI null mutant mice
In initial experiments, normal reproductive function was
observed in crosses between h2GPI-deficient male and
female mice [83] with reproductive outcomes indistinguish-
able from control mice in both males and females carrying
the h2GPI null mutation in terms of the proportion of
animals that bred successfully and the number and viability
of pups born at term and surviving to weaning. Furthermore,
there was no evidence of altered blood platelet counts in
either virgin or pregnant mice. New data from mating of
h2GPI-deficient mice confirm that h2GPI-deficient mice do
show any evidence of fetal loss late in gestation and have
normal growth trajectories both in utero and after birth
(Robertson et al., unpublished observations). Together, these
data preclude h2GPI from being essential for normal repro-
ductive function in mice.
However, there are observations that suggest homozy-
gote null mutant embryos may be less viable under some
circumstances than heterozygote or wild-type littermates.
When h2GPI heterozygotes on a 129/Sv/C57BL/6 mixed
genetic background were intercrossed, only 8.9% of the
resulting offspring were homozygous for the deletion, which
is significantly lower than the expected 1:2:1 Mendelian
ratio [83]. This finding implies that lack of h2GPI action
confers a selective disadvantage to survival. This is proba-
bly the result of a defect at implantation or at even earlier
reproductive stages, as litter sizes were comparable in
heterozygote and wild-type pregnancies. Furthermore, stud-
ies with larger cohorts of null mutant mice have revealed
that h2GPI deficiency is associated with a 15% reduction in
litter size, compared to heterozygote and wild-type preg-
nancies, along with subtle changes in placental size and
structure indicative of impaired placental efficiency (Rob-
ertson et al., unpublished observations). Taken together, the
above data indicate that h2GPI seems to play a facilitating
role in the initial stages of pregnancy in mice, but it is still
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unclear if this reflects an impact at the time of ovulation,
early embryogenesis, or implantation.
It is difficult to reconcile the observations of essentially
normal pregnancy outcomes in h2GPI-deficient mice with
negative selection pressure for h2GPI null offspring in
heterozygote mating. An explanation for this might be
found in the genetic background of the mice used in these
experiments, which were hybrids between the C57BL/6 and
129/Sv strains. A reasonable postulate is that at least in part
the reproductive phenotype is attributable to genetic modi-
fiers; for example, that the penetrance of the phenotype is a
consequence of variance in another gene or genes. While
sophisticated strategies would be required to identify such
genes, some support for this hypothesis comes from obser-
vations that during the initial generation of the null mutant
line, only one of four founding transgenic pairs produced
progeny over a 3-month breeding interval (S.A. Krilis,
unpublished observation), and all subsequent experimental
mice were derived from that pair. Furthermore, it might be
postulated that the h2GPI status of the mother has an
influence on the viability of a h2GPI-deficient conceptus.
The h2GPI null model also promises to provide impor-
tant insights concerning the role of aPL in pregnancy loss.
In preliminary experiments, we have shown that passive
transfer into pregnant mice of at least one monoclonal
antibody against human h2GPI and one polyclonal human
IgG antibody (derived from a patient with APS and associ-
ated recurrent miscarriages) causes complete pregnancy loss
in a significant proportion of pregnancies. Importantly
however, this effect could not be reproduced in pregnant
h2GPI-deficient mice, and only some antibodies reactive
with h2GPI were effective (Robertson et al., unpublished
observations). Perhaps surprisingly, the results show that
loss is not associated with placental thrombosis or clotting
changes, but rather occurs before or early after embryo
implantation. This is of interest in view of the observations
of early loss of h2GPI-deficient embryos [83]. These data,
combined with the finding that h2GPI is not essential for
successful reproductive function, imply that the mechanism
of aPL-associated pregnancy loss does not involve deacti-
vation of h2GPI, but rather is the consequence of an event
triggered via interaction of aPL with the h2GPI ligand. The
result is thus consistent with emerging theories of h2GPI-
mediated endothelial cell activation [55] or complement-
mediated endothelial cell or trophoblast cell damage
[48,62]. The caveat to this interpretation lies in our obser-
vation of variable susceptibility of individual mice to
treatment with different h2GPI-reactive aPL. It is unclear
whether the variance reflects differences among mice in
their outbred genetic background, a factor known to be
import in thrombotic events [84]. Alternatively, since early
pregnancy is notoriously sensitive to environmental stres-
sors such as LPS [85], a further possibility is that exogenous
influences interfere with the effect of aPL. Such a scenario
seems reasonable in view of the discovery that antibodies
binding to h2GPI can activate toll-like receptor-driven NF
kappa B signaling [56]. Further studies are therefore re-
quired to either validate or reject the hypothesis of h2GPI
involvement in early reproductive stages as an underlying
pathogenetic mechanism for recurrent fetal loss in APS.
Experiments in h2GPI knockout mice, including backcross-
ing onto a pure C57BL/6 background and investigation of
the interaction among h2GPI, aPL, and proinflammatory
mediators such as LPS, will help clarify the exact role of
h2GPI in reproductive events and APL-mediated fetal loss.
The coagulation cascade in b2GPI null mutant mice
While interactions between h2GPI and several factors of
the coagulation cascade have been reported, controversy
exists about the effect of h2GPI on coagulation. Some
important data recently came from studies on h2GPI-
deficient mice; these mice show a significantly diminished
rate of thrombin generation compared with h2GPI-replete
(h2GPI +/+) or even with heterozygous mice [83]. Fur-
thermore, the effect of h2GPI on thrombin generation was
dose dependent. On the contrary, however, no significant
differences in clotting time were observed in plasma from
these three genotypes when measured by dRVVT, dKCT,
aPTT, and protein C pathway assays. The fact that con-
ventional coagulation assays failed to detect any abnor-
malities in h2GPI-deficient mice is not inconsistent with
the above findings, as these tests measure the time to
generate a thrombin-dependent clot, which is a poor
indicator of thrombin generation, occurring before peak
thrombin production [86].
This interesting effect of h2GPI on thrombin confirmed
previous experiments from the same group where prolon-
gation of thrombin generation was observed following the
addition of anti-h2GPI antibodies to normal human plasma,
regardless of whether the antibody was of mouse mono-
clonalor APS patient origin [87]. Experiments on h2GPI
knockout mice gave direct evidence on the role of the
protein in the coagulation cascade, at least in one stage
upstream thrombin generation. However, it is still unclear if
the overall action of h2GPI is procoagulant or anticoagulant
since (1) generation of thrombin is important for both
thrombus formation and for the initiation of the protein C
anticoagulation pathway, and (2) other in vitro interactions
of h2GPI with other coagulation factors have been de-
scribed. It is expected that further research on the mouse
model lacking h2GPI will provide clarification.
Future perspectives
It is evident that the h2GPI-deficient mouse offers a
valuable tool for elucidating the role of h2GPI in homeo-
stasis and in APS. The model has the considerable benefit of
allowing the role of this molecule to be interrogated against
the complexity of the in vivo environment. In contrast to use
of aPL to neutralize h2GPI, the model eliminates the
confounding effects of marked heterogeneity in aPL antigen
and epitope specificity [88]. Furthermore, null mutant mice
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permit experiments to strategically address questions relat-
ing to the mechanisms of action underlying the pathogenesis
of APS. The mice have already provided new insights into
the function of h2GPI in normal and pathological processes
and further questions have now emerged. Among these are
the following: (1) Is there an effect of genetic background
on the penetrance of the h2GPI-deficient phenotype, and if
so what are the relevant interacting genes? (2) What stage of
conception or early pregnancy is compromised in the
absence of h2GPI? (3) Are there genetic or environmental
factors that explain why h2GPI-replete mice are differen-
tially affected by h2GPI-reactive aPL? (4) Are there differ-
ences in epitope reactivity or avidity that explain why some
aPL targeting h2GPI fail to exert any effect on the outcome
of murine pregnancies?
Additional challenging questions arise from experiments
evaluating the biological function of h2GPI in the coagula-
tion cascade: (1) Is the main action of h2GPI in the
coagulation cascade procoagulant or anticoagulant? (2) Is
this putative action mediated only by impairment of throm-
bin generation, given the numerous proposed interactions of
h2GPI with coagulation molecules? Furthermore, is there
any role for h2GPI in atherogenesis, and how do mice
lacking h2GPI behave under various dietary conditions?
Ongoing research in h2GPI-deficient mice is expected to
contribute significantly to unraveling the role of h2GPI and
of antibodies reactive with h2GPI in the pathogenesis of the
various clinical manifestations of APS.
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